このページの翻訳は実験的なもので、現在開発中です。お待ちしております

NovoCure マネジメント

マネジメント基準チェック /44

NovoCure'sの CEO はAsaf Danzigerで、 Jan2002年に任命され、の在任期間は 22.58年です。の年間総報酬は$ 1.52Mで、 49.7%給与と50.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.014%を直接所有しており、その価値は$ 272.55K 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と6.8年です。

主要情報

Asaf Danziger

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	49.7%
CEO在任期間	22.6yrs
CEOの所有権	0.01%
経営陣の平均在職期間	3.9yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

CEO報酬分析

NovoCure の収益と比較して、Asaf Danziger の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$169m
Mar 31 2024	n/a	n/a	-US$193m
Dec 31 2023	US$2m	US$756k	-US$207m
Sep 30 2023	n/a	n/a	-US$197m
Jun 30 2023	n/a	n/a	-US$174m
Mar 31 2023	n/a	n/a	-US$141m
Dec 31 2022	US$2m	US$831k	-US$93m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$68m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$1m	US$876k	-US$58m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	US$12m
Dec 31 2020	US$9m	US$782k	US$20m
Sep 30 2020	n/a	n/a	US$19m
Jun 30 2020	n/a	n/a	US$12m
Mar 31 2020	n/a	n/a	US$9m
Dec 31 2019	US$7m	US$702k	-US$7m
Sep 30 2019	n/a	n/a	-US$27m
Jun 30 2019	n/a	n/a	-US$41m
Mar 31 2019	n/a	n/a	-US$55m
Dec 31 2018	US$5m	US$693k	-US$64m
Sep 30 2018	n/a	n/a	-US$59m
Jun 30 2018	n/a	n/a	-US$59m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$4m	US$698k	-US$62m

報酬と市場: Asafの総報酬 ($USD 1.52M ) は、 US市場 ($USD 5.62M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Asafの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Asaf Danziger (58 yo)

22.6yrs

在職期間

US$1,521,026

報酬

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
William Doyle	Executive Chairman	20.6yrs	US$1.43m	0.51% $ 9.9m
Asaf Danziger	CEO & Director	22.6yrs	US$1.52m	0.014% $ 274.4k
Ashley Cordova	Chief Financial Officer	3.9yrs	US$6.32m	0.085% $ 1.6m
Wilhelmus C. Groenhuysen	Chief Operating Officer	3.9yrs	US$5.97m	0.28% $ 5.5m
Barak Arye	General Counsel	2.3yrs	US$4.86m	0.019% $ 379.5k
Frank Leonard	Executive VP & President of Novocure Oncology	3.9yrs	US$5.04m	0.053% $ 1.0m
Yoram Palti	Founder & CTO	24.6yrs	US$282.51k	データなし
Moshe Giladi	Chief Science Officer	1.6yrs	データなし	0.0065% $ 126.4k
Ingrid Goldberg	VP of Investor Relations	no data	データなし	データなし
Michael Puri	Chief Human Resources Officer	less than a year	データなし	0.0016% $ 31.2k
Uri Weinberg	Chief Innovation Officer	1.6yrs	データなし	0.057% $ 1.1m
Piet Hinoul	Senior VP	no data	データなし	データなし

3.9yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: NVCRの経営陣は経験豊富であると考えられます ( 3.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
William Doyle	Executive Chairman	20.6yrs	US$1.43m	0.51% $ 9.9m
Asaf Danziger	CEO & Director	12.6yrs	US$1.52m	0.014% $ 274.4k
Jeryl Hilleman	Independent Director	6.1yrs	US$446.09k	0.0023% $ 45.6k
David Hung	Independent Director	6.3yrs	US$426.09k	0.0084% $ 164.8k
Timothy Scannell	Independent Director	3.5yrs	US$448.53k	0.0036% $ 70.8k
Kinyip Leung	Independent Director	12.8yrs	US$435.53k	0.073% $ 1.4m
William Vernon	Lead Independent Director	18.6yrs	US$475.53k	0.15% $ 2.9m
Martin Madden	Independent Director	7.3yrs	US$446.09k	0.014% $ 281.4k
Kristin Stafford	Independent Director	1.4yrs	US$696.94k	0% $ 0
Allyson Ocean	Independent Director	1.5yrs	US$697.26k	0% $ 0

6.8yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: NVCRの取締役会は経験豊富であると考えられます ( 6.6年の平均在任期間)。

NovoCure マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Chief Operating Officer exercised options to buy US$2.7m worth of stock.

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited Announces Executive Changes

Chief Financial Officer exercised options to buy US$231k worth of stock.

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Recent updates

Consensus estimates of losses per share improve by 15%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited: A Post Q2 Analysis

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Chief Operating Officer exercised options to buy US$2.7m worth of stock.

Now 22% undervalued

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

Now 22% undervalued

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Q1 Earnings: Core Business Accelerating

NovoCure Limited announced that it expects to receive $400 million in funding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$82.00

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Consensus EPS estimates fall by 12%

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Consensus EPS estimates fall by 31%

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Novocure Announces Executive Changes

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

President notifies of intention to sell stock

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Price target increased to US$98.86

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

マネジメント基準チェック /44